Clinical Characteristics and Predictors of Survival in Adults with Coronavirus Disease 2019 Receiving Tocilizumab
Overview
Authors
Affiliations
Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction and death. The purpose of the present study is to determine clinical characteristics associated with 28 day in-hospital survival in patients with coronavirus disease 2019 (COVID-19) that received tocilizumab. This was a retrospective observational cohort study conducted at a five hospital health system in Michigan, United States. Adult patients with confirmed COVID-19 that were admitted to the hospital and received tocilizumab for cytokine storm from March 1, 2020 through April 3, 2020 were included. Patients were grouped into survivors and non-survivors based on 28 day in-hospital mortality. Study day 0 was defined as the day tocilizumab was administered. Factors independently associated with in-hospital survival at 28 days after tocilizumab administration were assessed. Epidemiologic, demographic, laboratory, prognostic scores, treatment, and outcome data were collected and analyzed. Clinical response was collected and defined as a decline of two levels on a six-point ordinal scale of clinical status or discharged alive from the hospital. Of the 81 patients included, the median age was 64 (58-71) years and 56 (69.1%) were male. The 28 day in-hospital mortality was 43.2%. There were 46 (56.8%) patients in the survivors and 35 (43.2%) in the non-survivors group. On study day 0 no differences were noted in demographics, clinical characteristics, severity of illness scores, or treatments received between survivors and non-survivors. C-reactive protein was significantly higher in the non-survivors compared to survivors. Compared to non-survivors, recipients of tocilizumab within 12 days of symptom onset was independently associated with survival (adjusted OR: 0.296, 95% CI: 0.098-0.889). SOFA score ≥8 on day 0 was independently associated with mortality (adjusted OR: 2.842, 95% CI: 1.042-7.753). Clinical response occurred more commonly in survivors than non-survivors (80.4% vs. 5.7%; p < 0.001). Improvements in the six-point ordinal scale and SOFA score were observed in survivors after tocilizumab. Early receipt of tocilizumab in patients with severe COVID-19 was an independent predictor for in-hospital survival at 28 days.
Liang P, Li Y, Meng L, Li Y, Mai H, Li T Sci Rep. 2024; 14(1):29634.
PMID: 39609511 PMC: 11605089. DOI: 10.1038/s41598-024-81028-3.
The sharp edge of immunosuppressive treatments: infections.
Ozsahin A, Ilgar T, Mahmutoglu Colak S, Akyuz K, Gozukara M, Kostakoglu U Turk J Med Sci. 2024; 54(4):752-760.
PMID: 39295623 PMC: 11407327. DOI: 10.55730/1300-0144.5845.
Aljuhani O, Al Sulaiman K, Korayem G, Alharbi A, Altebainawi A, Aldkheel S Ren Fail. 2023; 45(2):2268213.
PMID: 37870869 PMC: 11001317. DOI: 10.1080/0886022X.2023.2268213.
Velez A, Handley G, Morison A, Katzman J, Kinkhova O, Quiltz R Cancer Control. 2023; 30:10732748231205864.
PMID: 37817417 PMC: 10566286. DOI: 10.1177/10732748231205864.
Fadel R, Scott A, Parsons A, Murskyj I, Nasiri N, Sayf A J Intensive Care Med. 2023; 38(11):1042-1050.
PMID: 37306148 PMC: 10261959. DOI: 10.1177/08850666231180528.